DiaCarta, a US-China molecular cancer diagnostics company, obtained US-China rights to launch a non-invasive “liquid biopsy” test developed by Pangaea Biotech of Spain. The test detects genetic material in the blood of cancer patients. The Pangaea test, which is available for EGFR, KRAS and BRAF gene mutations, allows oncologists to personalize treatment by monitoring a patient’s response in real time, switching therapies if necessary. The tests are intended for use in lung, colon, pancreatic and breast cancer as well as melanoma.
